These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27297847)

  • 1. Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
    Doll JA; Wang TY; Choudhry NK; Cannon CP; Cohen DJ; Fonarow GC; Henry TD; Bhandary DD; Khan N; Davidson-Ray LD; Anstrom K; Peterson ED
    Am Heart J; 2016 Jul; 177():33-41. PubMed ID: 27297847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 Jan; 5(1):38-46. PubMed ID: 31721978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Anstrom KJ; Fonarow GC; Henry TD; Cannon CP; Choudhry NK; Cohen DJ; Atreja N; Bhalla N; Eudicone JM; Wang TY
    Circ Cardiovasc Qual Outcomes; 2020 May; 13(5):e006182. PubMed ID: 32393129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs.
    Doll JA; Kaltenbach LA; Anstrom KJ; Cannon CP; Henry TD; Fonarow GC; Choudhry NK; Fonseca E; Bhalla N; Eudicone JM; Peterson ED; Wang TY
    J Am Heart Assoc; 2020 Apr; 9(8):e014975. PubMed ID: 32299284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.
    Wang TY; Kaltenbach LA; Cannon CP; Fonarow GC; Choudhry NK; Henry TD; Cohen DJ; Bhandary D; Khan ND; Anstrom KJ; Peterson ED
    JAMA; 2019 Jan; 321(1):44-55. PubMed ID: 30620370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-Of-Pocket Expenses? Insights From ARTEMIS.
    Rymer JA; Kaltenbach LA; Peterson ED; Cohen DJ; Fonarow GC; Choudhry NK; Henry TD; Cannon CP; Wang TY
    J Am Heart Assoc; 2022 Oct; 11(20):e026421. PubMed ID: 36250667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 May; 5(5):532-539. PubMed ID: 32129795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet therapy beyond 2012: role of personalized medicine.
    Tantry US; Budaj A; Gurbel PA
    Pol Arch Med Wewn; 2012; 122(6):298-305. PubMed ID: 22751292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT).
    Déry JP; Mehta SR; Fisher HN; Zhang X; Zhu YE; Welsh RC; Lavi S; Cieza T; Henderson MA; Lutchmedial S; Siega AJ; Cheema AN; Wong BY; Kokis A; Dehghani P; Goodman SG;
    Am Heart J; 2016 Nov; 181():26-34. PubMed ID: 27823690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
    Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C;
    Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
    Guimarães PO; Tricoci P
    Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor adherence to P2Y12 antagonists increased cardiovascular risks in Chinese PCI-treated patients.
    Sun Y; Li C; Zhang L; Hu D; Zhang X; Yu T; Tao M; Wang DW; Shen X
    Front Med; 2017 Mar; 11(1):53-61. PubMed ID: 28213881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of pre- and posthospital medication adherence in myocardial infarction patients.
    Doll JA; Hellkamp AS; Thomas L; Fonarow GC; Peterson E; Wang TY
    Am Heart J; 2019 Feb; 208():74-80. PubMed ID: 30580129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
    Bavishi C; Panwar S; Messerli FH; Bangalore S
    Am J Cardiol; 2015 Sep; 116(5):809-17. PubMed ID: 26119655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Change in Employment Status After Acute Myocardial Infarction: Analysis From the TRANSLATE-ACS Study.
    Warraich HJ; Kaltenbach LA; Fonarow GC; Peterson ED; Wang TY
    Circ Cardiovasc Qual Outcomes; 2018 Jun; 11(6):e004528. PubMed ID: 29895612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
    Bonaca MP; Bhatt DL; Steg PG; Storey RF; Cohen M; Im K; Oude Ophuis T; Budaj A; Goto S; López-Sendón J; Diaz R; Dalby A; Van de Werf F; Ardissino D; Montalescot G; Aylward P; Magnani G; Jensen EC; Held P; Braunwald E; Sabatine MS
    Eur Heart J; 2016 Apr; 37(14):1133-42. PubMed ID: 26491109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.